t2c 001

Drug Profile

t2c 001

Alternative Names: Autologous bone marrow-derived mononuclear cell fraction; t2c001; t2c001-AMI; t2c001-CHD; t2c001-DCM; t2c001-SW

Latest Information Update: 28 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator t2cure
  • Class Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cardiomyopathies; Heart failure; Ischaemic heart disorders; Myocardial infarction; Thromboangiitis obliterans

Most Recent Events

  • 28 Jul 2015 No recent reports on development identified - Phase-I/II for Cardiomyopathy, Heart failure, Ischaemic heart disorders and Thromboangiitis obliterans in Germany (Intra-arterial)
  • 28 Jul 2015 No recent reports on development identified - Phase-II for Myocardial infarction in Germany (Intra-arterial)
  • 20 Sep 2010 t2c 001 receives Orphan Drug status for Thromboangiitis obliterans in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top